Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics

Xiaojun Feng; Antoni Sureda; Samineh Jafari; Zahra Memariani; Devesh Tewari; Giuseppe Annunziata; Luigi Barrea; Sherif T. S. Hassan; Karel Šmejkal; Milan Malaník; Alice Sychrová; Davide Barreca; Lovro Žiberna; Mohamad Fawzi Mahomoodally; Gökhan Zengin; Suowen Xu; Seyed Mohammad Nabavi; Ai-Zong Shen

doi:10.7150/thno.30787

Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics

Xiaojun Feng(University of Science and Technology of China), Antoni Sureda(Instituto de Salud Carlos III), Samineh Jafari(Zanjan University of Medical Sciences), Zahra Memariani(Babol University of Medical Sciences), Devesh Tewari(Lovely Professional University), Giuseppe Annunziata(Federico II University Hospital), Luigi Barrea(Istituto Nazionale di Fisica Nucleare, Sezione di Napoli), Sherif T. S. Hassan(University of Veterinary Sciences Brno), Karel Šmejkal(University of Veterinary Sciences Brno), Milan Malaník(University of Veterinary Sciences Brno), Alice Sychrová(University of Veterinary Sciences Brno), Davide Barreca(University of Messina), Lovro Žiberna(University of Ljubljana), Mohamad Fawzi Mahomoodally(University of Mauritius), Gökhan Zengin(Selçuk University), Suowen Xu(Rochester Institute of Technology), Seyed Mohammad Nabavi(Baqiyatallah University of Medical Sciences), Ai-Zong Shen(University of Science and Technology of China)

Theranostics

January 1, 2019

10.7150/thno.30787

Cited by 430Open Access

Full Text

Abstract

Cardiovascular and metabolic diseases (CVMD) are the leading causes of death worldwide, underscoring the urgent necessity to develop new pharmacotherapies. Berberine (BBR) is an eminent component of traditional Chinese and Ayurvedic medicine for more than 2000 years. Recently, BBR has attracted much interest for its pharmacological actions in treating and/or managing CVMD. Recent discoveries of basic, translational and clinical studies have identified many novel molecular targets of BBR (such as AMPK, SIRT1, LDLR, PCSK9, and PTP1B) and provided novel evidences supporting the promising therapeutic potential of BBR to combat CVMD. Thus, this review provides a timely overview of the pharmacological properties and therapeutic application of BBR in CVMD, and underlines recent pharmacological advances which validate BBR as a promising lead drug against CVMD.

Related Papers

No related papers found

Powered by citation graph analysis